The debate over substitution policy. Its evolution and scientific basis

Area of Science:

• Pharmacology
• Health Policy

Background:

• Drug quality and bioavailability are key considerations in generic substitution.
• National and state regulations regarding generic substitution vary significantly.
• Prescribing practices face challenges and changes due to generic and therapeutic substitution policies.

Purpose of the Study:

• To discuss differences in bioavailability between branded and generic drugs.
• To examine the regulatory landscape and legal variations in generic substitution.
• To highlight potential issues and inform optimal prescribing practices.

Main Methods:

• Review of current literature on drug bioavailability and generic substitution.
• Analysis of national and state-level regulations and laws.
• Discussion of clinical implications for various therapeutic categories and patient populations.

Main Results:

• Bioavailability can differ between brand-name and generic formulations, impacting therapeutic effectiveness.
• Regulatory environments and product selection laws exhibit considerable state-to-state variation.
• Potential problems with generic substitution exist, particularly for psychotropic, cardiovascular, and endocrine/metabolic drugs, and in vulnerable populations.

Conclusions:

• Physicians need to be informed about bioavailability variations and substitution laws for optimal prescribing.
• Generic substitution is intertwined with evolving policies on therapeutic substitution.
• Further consensus on the appropriate use of generic drugs is needed, considering specific patient needs and drug types.